The class of "RIKEN cDNA 4933416I08 Gene Inhibitors" is characterized by a diverse array of chemical compounds, each exhibiting unique biochemical properties that enable them to modulate various cellular signaling pathways. These compounds, though not directly linked to the RIKEN cDNA 4933416I08 gene due to the lack of specific scientific data, are known to influence key cellular processes that could indirectly impact the function of proteins encoded by this gene.
For instance, Axitinib and Pazopanib are known to inhibit tyrosine kinases involved in cell growth and angiogenesis, potentially altering signaling pathways that the RIKEN cDNA 4933416I08-encoded protein may participate in. Bosutinib and Dasatinib target specific tyrosine kinases like Src/Abl, thereby influencing cell proliferation and survival. Similarly, Crizotinib's inhibition of ALK, MET, and ROS1 tyrosine kinases can affect pathways related to cell differentiation and growth.
Erlotinib and Gefitinib specifically inhibit the EGFR tyrosine kinase, a key player in many cellular signaling pathways related to proliferation and apoptosis. Imatinib, targeting BCR-ABL, c-KIT, and PDGFR tyrosine kinases, impacts multiple pathways involved in cell proliferation and survival. Lapatinib's dual inhibition of EGFR and HER2 tyrosine kinases makes it significant in affecting pathways related to cell growth and survival.
Nilotinib's selective inhibition of BCR-ABL tyrosine kinase highlights its potential in influencing specific cell signaling pathways. Sorafenib and Sunitinib, by inhibiting multiple tyrosine kinases, exhibit a broad spectrum of activity affecting processes like cell proliferation, angiogenesis, and apoptosis.
These chemicals represent a comprehensive approach to understanding and modulating cellular signaling pathways. They provide insights into how different biochemical interactions can influence the activity of proteins encoded by genes like the RIKEN cDNA 4933416I08. By acting at various levels of cellular signaling, from receptor tyrosine kinases to downstream signaling molecules, these inhibitors contribute to our understanding of the complex network of interactions within the cell. Their diverse mechanisms of action highlight the intricate balance of cellular processes and offer a window into the potential regulation of proteins similar to those encoded by the RIKEN cDNA 4933416I08 gene.
製品名 | CAS # | カタログ # | 数量 | 価格 | 引用文献 | レーティング |
---|---|---|---|---|---|---|
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
幅広いチロシンキナーゼ阻害剤であり、細胞増殖と生存に関与する複数のシグナル伝達経路に影響を及ぼす可能性がある。 | ||||||
Erlotinib Hydrochloride | 183319-69-9 | sc-202154 sc-202154A | 10 mg 25 mg | $74.00 $119.00 | 33 | |
EGFRチロシンキナーゼを阻害し、細胞増殖とアポトーシス経路に影響を及ぼす可能性がある。 | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
EGFRチロシンキナーゼを標的とし、細胞の増殖と分裂に関与するシグナル伝達経路に影響を及ぼす可能性がある。 | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
BCR-ABL、c-KIT、PDGFRチロシンキナーゼを阻害し、細胞増殖およびアポトーシス経路に影響を及ぼす可能性がある。 | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
EGFRおよびHER2チロシンキナーゼの二重阻害剤であり、細胞の増殖および生存経路に影響を及ぼす可能性がある。 | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $205.00 $405.00 | 9 | |
BCR-ABLチロシンキナーゼを選択的に阻害し、細胞増殖とシグナル伝達経路に影響を及ぼす可能性がある。 | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $127.00 $178.00 | 2 | |
VEGFR、PDGFR、およびKITチロシンキナーゼを阻害し、血管新生および細胞増殖経路に影響を与える可能性があります。 | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
複数のチロシンキナーゼを阻害し、細胞増殖、血管新生、アポトーシス経路に影響を及ぼす可能性がある。 | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
様々なチロシンキナーゼを阻害し、血管新生や腫瘍細胞の増殖に影響を及ぼす可能性がある。 |